Table 3.

Viral subtype, coreceptor usage, and infectivity reduction by CCR5 specific Igs from LTNP

		Coreceptor usage	IC50/IC90, μg/mL
Viruses	Strain		4	11	20	21	22	152	110	173	NY4	NY6	NY9	NY10	HC*
HIV-36	B	R5	0.85/> 2	0.64/> 2	0.42/> 2	0.27/1.8	0.42/> 2	ND	ND	ND	> 2/> 2	> 2/> 2	> 2/> 2	> 2/> 2	> 45/> 45
HIV-40	B	R5	0.51/> 2	0.60/> 2	0.96/1.7	0.28/1.9	0.46/1.5	ND	ND	ND	0.89/> 2	0.88/> 2	0.56/> 2	1.4/> 2	> 45/> 45
92BR025	C	R5	ND	ND	0.45/> 2	1.9/> 2	0.8/> 2	ND	ND	ND	ND	ND	ND	ND	> 45/> 45
92TH007	A	R5	ND	ND	0.01/> 2	2/> 2	0.7/> 2	ND	ND	ND	ND	ND	ND	ND	> 45/> 45
HIV-45	B	X4, R5, R3	> 2/> 2	> 2/> 2	> 2/> 2	> 2/> 2	> 2/> 2	ND	ND	ND	> 2/> 2	> 2/> 2	> 2/> 2	> 2/> 2	> 45/> 45
HIV-26	B	X4	ND	ND	> 2/> 2	> 2/> 2	> 2/> 2	ND	ND	ND	ND	ND	ND	ND	> 45/> 45
SOS/HIV	JRFL	R5	0.5/2.9	1.1/6.1	0.4/2.2	0.6/3.3	0.8/4.4	1.2/6.7	1.3/7.2	1/5.9	ND	ND	ND	ND	> 45/> 45
SOS/VSV-G	NA	NA	> 10/> 10	> 10/> 10	> 10/> 10	> 10/> 10	> 10/> 10	> 10/> 10	> 10/> 10	> 10/> 10	ND	ND	ND	ND	> 45/> 45

The values are expressed as Ig concentration (μg/mL) inhibiting 50% (IC₅₀) and 90% (IC₉₀) virus replication. The results are representative of 3 independent experiments. Six primary isolates were used to infect PBMCs from HCs, and 2 viral molecular clones (SOS/HIV/JRFL and an HIV-unrelated clone SOS/VSV-G) were used to infect CCR5-U87 cells.

ND indicates not done; NA, not applicable.

^*A pool of total serum Ig from 5 HCs was used as negative control (HC). The highest Ig concentration tested in neutralization assay was 45 and 10 μg/mL for HCs and LTNsP, respectively.